Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-CIN vaccine in HPV16-associated cervical cancer
NCT02405221Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TA-CIN in Cervical Cancer (CC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of Participants with treatment-related Adverse Events at 4 years. Started Apr 2019; status: completed.
02
Drugs
TA-CIN
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02405221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405221.